ARCH:CA:CDX-Arch Biopartners Inc. (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 1.81

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Arch Biopartners Inc is a biotechnology company. The Companis engaged in development of technologies that have the potential to make a medical or commercial impact. Its portfolio includes AB569, MetaMx, MetaBlok, Borg, and Arch Inflammation.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.19B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.08B
MIR:CA MedMira Inc

N/A

USD 0.06B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.02B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
SBM:CA Sirona Biochem Corp

N/A

USD 0.02B
HEM:CA Hemostemix Inc

N/A

USD 8.28M
RKV:CA Rakovina Therapeutics Inc

N/A

USD 7.67M

ETFs Containing ARCH:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.30% 47% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.30% 47% F 60% D-
Trailing 12 Months  
Capital Gain 66.06% 63% D 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.06% 63% D 74% C
Trailing 5 Years  
Capital Gain 92.55% 58% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 92.55% 58% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 30.25% N/A N/A 75% C
Dividend Return 30.25% N/A N/A 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 79.16% N/A N/A 36% F
Risk Adjusted Return 38.22% N/A N/A 83% B
Market Capitalization 0.02B 94% A 93% A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.